Vandria develops first-in-class small molecules targeting a novel metabolic pathway to treat age-related diseases. The company focuses on improving mitochondrial function and reducing chronic inflammation across multiple indications. Its pipeline includes novel New Chemical Entities (NCEs) for CNS, muscle, lung, and liver disorders, with a lead clinical asset in Phase I trials.
Funding
$32.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NCHFounders
Product
Problem
Age-related and chronic diseases are often linked to the accumulation of damaged mitochondria within cells, leading to cellular dysfunction and impaired tissue health. Current therapeutic approaches often fail to specifically target and remove these dysfunctional mitochondria, limiting their effectiveness in restoring cellular health.
Solution
Vandria is developing a new class of mitophagy inducers designed to selectively remove dysfunctional mitochondria and promote cellular renewal. These compounds enhance the natural cellular process of mitophagy, which is responsible for clearing damaged mitochondria. By specifically targeting mitochondrial dysfunction, Vandria's therapeutics aim to improve cellular health, restore tissue function, and combat the progression of age-related and chronic diseases. This targeted approach offers the potential for more effective and precise interventions compared to broad-spectrum treatments.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing therapeutics for age-related diseases, neurodegenerative disorders, and metabolic diseases.
Features
- Small molecule mitophagy inducers with enhanced selectivity for dysfunctional mitochondria
- Optimized compounds designed for improved cellular uptake and bioavailability
- Preclinical validation demonstrating efficacy in relevant disease models
- Proprietary screening platform for identifying novel mitophagy-inducing compounds